Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Choice nonprescription, too

This article was originally published in The Tan Sheet

Executive Summary

Watson Laboratories receives FDA's clearance for nonprescription sale of its Next Choice emergency contraceptive - a generic verson of Plan B (levonorgestrel 1.5 mg) - to consumers 17 and older as Plan B's original period of nonprescription exclusivity runs out for Teva Pharmaceutical Industries. Watson began shipping nonprescription Next Choice to major retail drug chains shortly after FDA's Aug. 28 approval of its abbreviated new drug application, with pharmacies in some markets expected to start selling the product the next day, said Patty Eisenhaur, the firm's VP of investor relations and corporate communications. The subsidiary of Morristown, N.J.-based Watson Pharmaceuticals previously received FDA's OK to market Next Choice as a prescription product and began shipping it early this summer. Teva carved out another three years of exclusivity in the branded nonprescription EC market with FDA's July approval of Plan B One-Step, which combines the two 0.75-mg doses of the original product into a single tablet (1"The Tan Sheet" July 20, 2009)

You may also be interested in...



With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics

Teva Pharmaceutical Industries likely will gain another three years of exclusivity in the branded nonprescription emergency contraceptive market with FDA's approval of a revised dosage of Plan B

Valneva Starts COVID-19 Vaccine Production In Scotland

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

Stakeholders To Have Say On Future Medicines Verification System In UK

The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel